FDA Accepts Vanda Pharmaceuticals’ BLA for Imsidolimab in Generalized Pustular Psoriasis

WASHINGTON, Feb. 25, 2026 – The U.S. Food and Drug Administration (FDA) has accepted Vanda Pharmaceuticals Inc.’s (Nasdaq: VNDA) Biologics License Application (BLA) for imsidolimab, a novel therapy for Generalized Pustular Psoriasis (GPP). The FDA assigned a target action date of December 12, 2026, for its review of the application.

Understanding Generalized Pustular Psoriasis

GPP is a rare, chronic, and potentially life-threatening autoinflammatory skin disorder. It’s characterized by widespread outbreaks of pustules, skin redness (erythema), and systemic symptoms like fever and fatigue. The underlying cause of GPP is increasingly understood through genetic research, with excessive activity of the interleukin-36 (IL-36) pathway playing a central role. ¹

Specifically, the majority of GPP cases with a known genetic cause are linked to mutations in the IL36RN gene, which encodes the IL-36 receptor antagonist (IL-36Ra). ¹

How Imsidolimab Works

Imsidolimab is a fully humanized IgG4 monoclonal antibody designed to inhibit IL-36 receptor signaling. By blocking this pathway, imsidolimab aims to restore balance in patients with GPP where IL-36 signaling is overactive. ¹

Clinical Trial Results

The BLA submission is supported by data from the Phase 3 GEMINI-1 and GEMINI-2 studies. Results showed that a single intravenous dose of imsidolimab led to rapid improvement in skin condition, with 53% of patients achieving clear or almost clear skin (GPPPGA 0/1) at Week 4, compared to 13% in the placebo group. ¹ This efficacy was maintained for approximately two years with monthly maintenance doses, and no flares were reported in the active treatment arm. Imsidolimab also demonstrated a favorable safety profile with a low incidence of anti-drug antibodies. ³

Prevalence and Unmet Need

GPP is a rare disease, with prevalence estimates ranging from 2 to 124 cases per million people worldwide, varying by geographic region. ⁴ This represents a significant unmet medical need for effective treatments.

Vanda Pharmaceuticals’ Perspective

“The acceptance of the BLA filing for imsidolimab marks a critical milestone in our efforts to bring this innovative therapy to patients suffering from GPP,” said Mihael H. Polymeropoulos, M.D., President, CEO, and Chairman of the Board of Vanda Pharmaceuticals. ⁴ “Imsidolimab builds on our growing expertise in rare orphan disorders and our anti-inflammatory portfolio.”

Recent Approvals and Future Outlook

If approved, imsidolimab would be Vanda’s third new drug approval in the past 12 months, following NEREUS™ (tradipitant) and BYSANTI™ (milsaperidone). ¹ The company anticipates regulatory and patent exclusivity for imsidolimab extending into the late 2030s.

Disclaimer: This article provides information based on publicly available sources as of February 25, 2026. It is not intended as medical advice.

1. Vanda Pharmaceuticals Announces FDA Acceptance of Biologics License Application Filing for Imsidolimab for the Treatment of Generalized Pustular Psoriasis
2. Vanda Announces Submission of Biologics License Application to the FDA for Imsidolimab for the Treatment of Generalized Pustular Psoriasis
3. Vanda FDA accepts imsidolimab BLA in pustular psoriasis | VNDA Stock News